A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease MAFLD

NCT06884293

Status	RECRUITING
Phase	Phase 3
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Enrollment	470 participants

Key Eligibility Criteria

Inclusion (6)

- Male or female, age 18 years or older at the time of signing informed consent
- diagnosed as MAFLD according to the Chinese Guideline for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)
- liver fat content e8% measured by MRI-PDFF
- BMIe27 kg/m2
- Weight change d5% within 3 months before screening

... and 1 more (see full listing online)

Exclusion (7)

- Subjects who the investigator thinks may be allergic to the components in the study drug or similar drugs
- Used drugs or alternative therapies with weight loss effects within 3 months before screening, including but not limited to: GLP-1 receptor agonists, orlistat, phenylpropanolamine, chlorpheniramine, phentermine etc.
- Received chronic (\>2 weeks) systemic glucocorticoid treatment within 3 months before screening (excluding topical, intraocular, intranasal, and inhaled administration)
- Previous diagnosis of type 1 diabetes (including adult latent autoimmune diabetes)
- Active or untreated malignant tumors within 5 years before screening, or patients are in remission of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery)

... and 2 more (see full listing online)

Locations (1 total)

Beijing Hospital, Beijing, Beijing Municipality, China